id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1978-N-0018-0837,FDA,FDA-1978-N-0018,"Appendix IV- Avobenzone/ Ti02 Combination re: Comment from L'Oreal USA Products, Inc. (Part 4 of 5)",Supporting & Related Material,Background Material,2018-10-26T04:00:00Z,2018,10,,,2020-01-31T06:55:37Z,,0,0,090000648055c042
FDA-1978-N-0018-0835,FDA,FDA-1978-N-0018,"Appendix II- Avobenzone/ Ti02 Combination re: Comment from L'Oreal USA Products, Inc. (Part 2 of 5)",Supporting & Related Material,Background Material,2018-10-26T04:00:00Z,2018,10,,,2019-08-02T15:00:59Z,,0,0,090000648055c039
FDA-1978-N-0018-0838,FDA,FDA-1978-N-0018,"Appendix V & VI- Avobenzone/ Ti02 Combination re: Comment from L'Oreal USA Products, Inc. (Part 5 of 5)",Supporting & Related Material,Background Material,2018-10-26T04:00:00Z,2018,10,,,2020-01-31T06:55:37Z,,0,0,090000648055c027
FDA-1978-N-0018-0836,FDA,FDA-1978-N-0018,"Appendix III- Avobenzone/ Ti02 Combination re: Comment from L'Oreal USA Products, Inc. (Part 3 of 5)",Supporting & Related Material,Background Material,2018-10-26T04:00:00Z,2018,10,,,2020-01-31T06:55:37Z,,0,0,090000648055c03d
FDA-1978-N-0018-0830,FDA,FDA-1978-N-0018,Letter from King and Spalding on behalf of Givaudan-Roure Corporation & Hoffmann-La Roche to FDA,Other,Letter(s),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-23T19:12:45Z,,0,0,090000648055a25a
FDA-1978-N-0018-0827,FDA,FDA-1978-N-0018,Appearance Request from Givaudan-Roure Corporation,Other,Appearance Request,2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-19T20:14:12Z,,0,0,090000648055a0e7
FDA-1978-N-0018-0825,FDA,FDA-1978-N-0018,Letter from King & Spalding to FDA/DDM,Other,Letter(s),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-23T18:37:30Z,,0,0,0900006480559da7
FDA-1978-N-0018-0826,FDA,FDA-1978-N-0018,Letter from King & Spalding on behalf of Givaudan-Roure Corporation to FDA/CDER,Other,Letter(s),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-23T16:56:06Z,,0,0,090000648055a05c
FDA-1978-N-0018-0828,FDA,FDA-1978-N-0018,Letter from King & Spalding on behalf of Givaudan-Roure Corporation to FDA,Other,Letter(s),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-19T19:55:47Z,,0,0,090000648055a1a7
FDA-1978-N-0018-0829,FDA,FDA-1978-N-0018,Supplement from King & Spalding on behalf of Givaudan-Roure Corporation,Other,Supplement (SUP),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-22T15:11:34Z,,0,0,090000648055a21f
FDA-1978-N-0018-0831,FDA,FDA-1978-N-0018,Supplement from Schering-Plough HealthCare Products (Vol 1 of 2),Other,Supplement (SUP),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-24T19:04:34Z,,0,0,090000648055a2cb
FDA-1978-N-0018-0832,FDA,FDA-1978-N-0018,Supplement from Schering-Plough HealthCare Products (Vol 2 of 2),Supporting & Related Material,Supplement (SUP),2018-04-05T04:00:00Z,2018,4,2018-04-05T04:00:00Z,,2019-07-24T19:57:30Z,,0,0,090000648055a2c6
FDA-1978-N-0018-0823,FDA,FDA-1978-N-0018,Letter from King & Spalding to FDA/CDER,Other,Letter(s),2018-04-03T04:00:00Z,2018,4,2018-04-03T04:00:00Z,,2019-08-01T20:02:43Z,,0,0,0900006480559c06
FDA-1978-N-0018-0821,FDA,FDA-1978-N-0018,Letter from King & Spalding on Behalf of Givaudan-Roure Corporation to FDA CDER,Other,Letter(s),2018-04-03T04:00:00Z,2018,4,2018-04-03T04:00:00Z,,2019-07-18T16:00:41Z,,0,0,0900006480559bed
FDA-1978-N-0018-0822,FDA,FDA-1978-N-0018,Letter from King & Spalding on behalf of Givaudan-Roure Corporation to FDA CDER,Other,Letter(s),2018-04-03T04:00:00Z,2018,4,2018-04-03T04:00:00Z,,2019-07-18T12:09:32Z,,0,0,0900006480559bf4
FDA-1978-N-0018-0820,FDA,FDA-1978-N-0018,Citizen Petition from Givaudan Corporation,Other,Citizen Petition,2018-04-03T04:00:00Z,2018,4,2018-04-03T04:00:00Z,,2019-07-16T17:08:07Z,,0,0,0900006480559b01